1
|
Cui M, Rong Q, Wang R, Ye D, Li N, Nian L. Zirconium Oxide Doped Organosilica Nanodots as Light- and Charge-Management Cathode Interlayer for Highly Efficient and Stable Inverted Organic Solar Cells. Small 2024:e2311339. [PMID: 38529739 DOI: 10.1002/smll.202311339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 02/28/2024] [Indexed: 03/27/2024]
Abstract
In this work, it is reported that zirconium oxide (ZrO2) doped organosilica nanodots (OSiNDs: ZrO2) with light- and charge-management properties serve as efficient cathode interlayers for high-efficiency inverted organic solar cells (i-OSCs). ZrO2 doping effectively improves the light harvesting of the active layer, the physical contact between the active layer, as well as the electron collection property by habiting charge recombination loss. Consequently, all devices utilizing the OSiNDs: ZrO2 cathode interlayer exhibit enhanced power conversion efficiency (PCE). Specifically, i-OSCs based on PM6:Y6 and PM6:BTP-eC9 achieve remarkable PCEs of 17.16% and 18.43%, respectively. Furthermore, the PCE of device based on PM6:Y6 maintains over 97.2% of its original value following AM 1.5G illumination (including UV light) at 100 mW cm-2 for 600 min.
Collapse
Affiliation(s)
- Mengqi Cui
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou, 510006, China
- Department of Electrical and Electronic Engineering, The University of Hong Kong, Pokfulam Road, Hong Kong, SAR, 999077, China
| | - Qikun Rong
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou, 510006, China
| | - Rong Wang
- Guangxi Key Lab of Agricultural Resources Chemistry and Biotechnology, College of Chemistry and Food Science, Yulin Normal University, 1303 Jiaoyudong Road, Yulin, 537000, China
| | - Dechao Ye
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou, 510006, China
| | - Na Li
- School of Information and Optoelectronic Science and Engineering, South China Normal University, Guangzhou, 510006, China
| | - Li Nian
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou, 510006, China
| |
Collapse
|
2
|
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023; 34:885-898. [PMID: 37597578 DOI: 10.1016/j.annonc.2023.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 08/03/2023] [Accepted: 08/08/2023] [Indexed: 08/21/2023] Open
Abstract
BACKGROUND HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (seven in each arm) from a randomized substudy of fulvestrant versus fulvestrant + trastuzumab (F + T) versus N + F + T. PATIENTS AND METHODS Patients with HR+ HER2-negative MBC with activating HER2 mutation(s) and prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy received N + F + T (oral neratinib 240 mg/day with loperamide prophylaxis, intramuscular fulvestrant 500 mg on days 1, 15, and 29 of cycle 1 then q4w, intravenous trastuzumab 8 mg/kg then 6 mg/kg q3w) or F + T or fulvestrant alone. Those whose disease progressed on F + T or fulvestrant could cross-over to N + F + T. Efficacy endpoints included investigator-assessed objective response rate (ORR), clinical benefit rate (RECIST v1.1), duration of response, and progression-free survival (PFS). Plasma and/or formalin-fixed paraffin-embedded tissue samples were collected at baseline; plasma was collected during and at end of treatment. Extracted DNA was analyzed by next-generation sequencing. RESULTS ORR for 57 N + F + T-treated patients was 39% [95% confidence interval (CI) 26% to 52%); median PFS was 8.3 months (95% CI 6.0-15.1 months). No responses occurred in fulvestrant- or F + T-treated patients; responses in patients crossing over to N + F + T supported the requirement for neratinib in the triplet. Responses were observed in patients with ductal and lobular histology, 1 or ≥1 HER2 mutations, and co-occurring HER3 mutations. Longitudinal circulating tumor DNA sequencing revealed acquisition of additional HER2 alterations, and mutations in genes including PIK3CA, enabling further precision targeting and possible re-response. CONCLUSIONS The benefit of N + F + T for HR+ HER2-mutant MBC after progression on CDK4/6is is clinically meaningful and, based on this study, N + F + T has been included in the National Comprehensive Cancer Network treatment guidelines. SUMMIT has improved our understanding of the translational implications of targeting HER2 mutations with neratinib-based therapy.
Collapse
Affiliation(s)
- K Jhaveri
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York.
| | - L D Eli
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - H Wildiers
- University Hospitals Leuven, Leuven, Belgium
| | - S A Hurvitz
- David Geffen School of Medicine, UCLA, Los Angeles, Santa Monica, USA
| | - A Guerrero-Zotano
- Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| | - N Unni
- UT Southwestern Medical Center, Dallas
| | - A Brufsky
- Magee-Womens Hospital of UPMC, Pittsburgh
| | - H Park
- Washington University School of Medicine, St. Louis
| | - J Waisman
- City of Hope Comprehensive Cancer Center, Duarte
| | - E S Yang
- University of Alabama at Birmingham, Birmingham, USA
| | - I Spanggaard
- Department of Oncology, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - S Reid
- Division of Hematology/Oncology (Breast Oncology), The Vanderbilt-Ingram Cancer Center, Nashville
| | - M E Burkard
- Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison
| | - S Vinayak
- Seattle Cancer Care Alliance, Seattle, USA
| | - A Prat
- Hospital Clínic de Barcelona, Barcelona, Spain
| | - M Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif
| | - F-C Bidard
- Department of Medical Oncology, UVSQ/Paris-Saclay University, Institut Curie, Saint Cloud, France
| | - S Loi
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne; The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia
| | - J Crown
- St. Vincent's University Hospital, Dublin, Ireland
| | - M Bhave
- Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta
| | - S A Piha-Paul
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston
| | - J M Suga
- Kaiser Permanente, Department of Medical Oncology, Vallejo, USA
| | - S Chia
- Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - C Saura
- Medical Oncology Service, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - J Á Garcia-Saenz
- Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid
| | - V Gambardella
- Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia
| | - M J de Miguel
- START Madrid - Hospital Universitario Madrid Sanchinarro, Madrid, Spain
| | - E N Gal-Yam
- Institute of Breast Oncology, Sheba Medical Center, Ramat Gan
| | - A Rapael
- Sourasky Medical Center, Tel Aviv
| | - S M Stemmer
- Davidoff Cancer Center, Rabin Medical Center, Petah Tikva; Tel Aviv University, Tel Aviv, Israel
| | - C Ma
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | - A B Hanker
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | - D Ye
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | | | - R Bose
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | - L Peterson
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | | | - A Frazier
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - D DiPrimeo
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - A Wong
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - C L Arteaga
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | - D B Solit
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
| |
Collapse
|
3
|
Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between Type 1 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization analysis. Osteoporos Int 2023; 34:1111-1117. [PMID: 37012460 DOI: 10.1007/s00198-023-06734-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 03/21/2023] [Indexed: 04/05/2023]
Abstract
We used two-sample Mendelian Randomization to reveal causal estimates of type 1 diabetes and bone. Type 1 diabetes was found to be a risk factor for bone metabolic health, although there was no clear evidence to support a genetic association between type 1 diabetes and osteoporosis and fracture risk. INTRODUCTION Based on the random assignment of gametes at conception, Mendelian randomization (MR) analysis simulates randomized controlled trials in an observational setting. Therefore, we used MR to assess the association causality of type 1 diabetes (T1D) with fractures and osteoporosis. METHODS From a genome-wide association meta-analysis, independent single nucleotide polymorphisms closely associated with T1D were selected as instrumental variables. Data on fracture and osteoporosis were obtained from the FinnGen Consortium. We performed a two-sample MR analysis, using inverse-variance weighted (IVW) as the primary analysis method, to assess possible causal associations between T1D and bone risk. The results were verified by MR-Egger regression and median weighted method (WME). MR-PRESSO and MR-Egger intercepts were used to evaluate the horizontal pleiotropy of instrumental variables, and the Q-test and "leave-one-out" methods were used to test the heterogeneity of MR results. RESULTS IVW (OR=1.040, 95% CI=0.974-1.109, P=0.238), MR-Egger regression (OR=1.077, 95% CI=0.921-1.260, P=0.372) and WME (OR=1.021, 95% CI=0.935-1.114, P=0.643) all showed that there was no causal relationship between T1D and osteoporosis, but the direction was consistent. The indicative significance of IVW results in T1D and forearm fractures (OR=1.062, 95% CI=1.010-1.117, P=0.020), but the results are not robust enough. There was no causal effect in femur, lumbar and pelvis, or shoulder and upper arm fractures. CONCLUSIONS After MR analysis, although T1D may be a risk factor for bone health, we do not have sufficient evidence to support a causal effect of T1D on osteoporosis and fractures at a genetically predicted level. More cases need to be included for analysis.
Collapse
Affiliation(s)
- Y Tang
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - L Zhang
- General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China
| | - D Ye
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - A Zhao
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Y Liu
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - M Zhang
- Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
| |
Collapse
|
4
|
Zhang H, Ye D, Zhu Y. ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC). Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00569-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
5
|
Ye D, Li S, Gan X, Misra R, Wang S, Liu Z, Hu C, Yang Y. In situ growth of carbon nanotubes on NiTi powder for printing high-performance NiTi matrix composite. POWDER TECHNOL 2023. [DOI: 10.1016/j.powtec.2023.118221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
6
|
Zhou L, Dai T, Zhang D, Guo H, Zhou F, Shi B, Wang S, Ji Z, Wang C, Yao X, Wei Q, Chen N, Xing J, Yang J, Kong C, Huang J, Ye D. 152P An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
7
|
Wei Y, Zhu Y, Ye D. 162MO Genomic characterization revealed from prospective clinical sequencing of 1016 Chinese prostate cancer patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
8
|
Necchi A, Bajorin D, Tomita Y, Ye D, Agerbaek M, Enting D, Peer A, Milowsky M, Kobayashi K, Grimm MO, Stenner F, David J, Li J, Chasalow S, Nasroulah F, Apfel A, Ünsal-Kaçmaz K, Galsky M. Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase 3 CheckMate 274 trial. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02582-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
9
|
Necchi A, Bajorin D, Tomita Y, Ye D, Agerbæk M, Enting D, Peer A, Milowsky M, Kobayashi K, Grimm MO, Stenner-Liewen F, David J, Li J, Chasalow S, Nasroulah F, Apfel A, Unsal-Kacmaz K, Galsky M. 1737MO Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Gu SS, Shen ZS, Deng HX, Qiu SJ, Ye D. [Cell heterogeneity of laryngeal carcinoma and evolution trajectory of epithelial cells]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:168-177. [PMID: 35196760 DOI: 10.3760/cma.j.cn115330-20211217-00805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To analyze the classification and functions of cell subsets in laryngeal carcinoma and metastatic lymph nodes, and to explore the evolution trajectory of epithelial cells to tumor cells. Methods: Single-cell RNA sequencing was performed on 5 cases of laryngeal cancer, matched metastatic lymph nodes and 3 normal tissues. Patients were admitted to Ningbo Medical Center Lihuili Hospital from October 22, 2019 to December 16, all patients were male, aged 53-70 years old. Cell subsets of the above-mentioned tissues were analyzed by the Seurat, and the biological functions of cell subpopulation were investigated by functional enrichment analysis. Malignant epithelial cells were identified using copy number variation (CNV). The evolutionary trajectory of epithelial cells to cancer cells was analyzed by cell trajectory analysis, and cancerous transitional cells were identified. The highly expressed genes in transitional cells were analyzed by the FindAllMarker of the Seurat and verified by immunohistochemistry. Results: A total of 66 969 high-quality cells were obtained in 9 major clusters: epithelial cells, T cells, B cells, fibroblasts, endothelial cells, myeloid cells, mast cells, plasmacytoid dendritic cells and nerve cells. The first 5 cell clusters were divided into 8, 6, 4, 3 and 2 subgroups, respectively. Four epithelial cell subsets (C0, C1, C2 and C5) were derived from tumor tissues and metastatic lymph nodes, and had high levels of CNV and tumor cell content. Cell trajectory analysis showed that the evolution trajectory of epithelial cells was from normal epithelial subpopulation C4 to early cancerous cell population C0, which differentiated into three major malignant cell subsets C1, C3, and C5. Epithelial cell C0 may represent the transitional cell population of carcinogenesis, and were enriched in biological processes such as epithelial-mesenchymal transformation and angiogenesis. C0 highly expressed sulforaphane (SFN) which may be related to the occurrence and development of cancer. Immunohistochemistry confirmed that SFN was highly expressed in tumor tissues and metastatic lymph nodes compared with paracancerous tissues. Conclusion: Single-cell sequencing may be used to elucidate the diversity of cells and functions in laryngeal carcinoma tissues and metastatic lymph nodes, and cell population C0 plays a key role in the evolution of cells.
Collapse
Affiliation(s)
- S S Gu
- Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, China
| | - Z S Shen
- Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, China
| | - H X Deng
- Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, China
| | - S J Qiu
- Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, China
| | - D Ye
- Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo 315040, China
| |
Collapse
|
11
|
Pan J, Ye D, Zhu Y. Stereotactic radiotherapy for 68Ga-PSMA and 18F-FDG PET/CT detected lesions in early non-metastatic castration-resistant prostate cancer (PSA≤2ng/ml): A prospective single-center study. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00289-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Huang J, Wang Y, Zhang C, Hu X, Wang P, Shi G, Dong L, Zhang J, Kong W, Chen Y, Ye D, Xia D, Guo J, Xue W, Huang Y, He Z. Surgical management and oncologic outcomes for local recurrence of renal cell carcinoma after radical nephrectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00460-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021; 6:100304. [PMID: 34864348 PMCID: PMC8645910 DOI: 10.1016/j.esmoop.2021.100304] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 09/22/2021] [Accepted: 10/17/2021] [Indexed: 01/05/2023] Open
Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of renal cell carcinoma was published in 2019 with an update planned for 2021. It was therefore decided by both the ESMO and the Singapore Society of Oncology (SSO) to convene a special, virtual guidelines meeting in May 2021 to adapt the ESMO 2019 guidelines to take into account the ethnic differences associated with the treatment of renal cell carcinomas in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with renal cell carcinoma representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate.
Collapse
Affiliation(s)
- R Kanesvaran
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
| | - C Porta
- Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro' and Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy
| | - A Wong
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
| | - T Powles
- Barts Cancer Institute, Queen Mary University, London, UK
| | - Q S Ng
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
| | - M Schmidinger
- Department of Urology I, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - D Ye
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - H Malhotra
- Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur, India
| | - Y Miura
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
| | - J L Lee
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - F L T Chong
- Department of Radiotherapy and Oncology, Sabah Women and Children's Hospital, Kota Kinabalu, Sabah, Malaysia
| | - Y-S Pu
- Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
| | - C-C Yen
- Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan
| | - M Saad
- Department of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
| | - H J Lee
- Department of Medical Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
| | - H Kitamura
- Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan
| | | | - G Curigliano
- Istituto Europeo di Oncologia, IRCCS and University of Milano, Milan, Italy
| | - E Poon
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
| | - S P Choo
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Medical Oncology, Curie Oncology, Singapore, Singapore
| | - S Peters
- Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - E Lim
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
| | - T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | | |
Collapse
|
14
|
Jin Y, Ye D, Geng H, Yu YQ, Zhang XX, Peng SY, Li JT. [A new classification of intrahepatic cholangiocarcinoma based on actual anatomy:a series of 135 cases]. Zhonghua Wai Ke Za Zhi 2021; 59:842-847. [PMID: 34619910 DOI: 10.3760/cma.j.cn112139-20210716-00313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the feasibility and clinical value of a new classification for resectable intrahepatic cholangiocarcinoma (IHCC) according to the actual anatomy. Methods: The data of 135 patients with IHCC who were admitted to the Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital of Zhejiang University School of Medicine from November 2011 to November 2020 after discussion by a multidisciplinary team and planned to undergo radical resection were analyzed retrospectively. There were 77 males and 58 females,with a median age of 61 years (range:26 to 86 years),of which 38 cases had vascular invasion. This new classification was carried out independently by two hepatobiliary surgeons. First,a preliminary classification was made based on the location of the tumor,and then the final classification was based on vascular invasion. All patients were followed up by telephone,and the follow-up was as of November 2020. Survival time is defined as the time after surgery to follow-up or death. Log-rank test was used to compare patients' median recurrence-free survival and overall survival time. The Cox proportional hazard model was used to analyze the prognosis factors of the overall survival time of patients with IHCC. Results: Among the 135 patients,129 underwent R0 resection and 6 underwent R1 resection. According to the actual anatomy,28 cases (20.7%) belonged to segmental type, 43 cases (31.9%) belonged to branch type, 64 cases (47.4%). The median survival time of all patients was 35.2 months(95%CI:21.3 to 70.5 months),the 1-year cumulative survival rate was 75.1%,the 3-year cumulative survival rate was 45.8%,and the 5-year cumulative survival rate was 39.0%. After grouping according to the classification,the median survival time of segmental patients was 36.9 months (more than 50% of patients reached the median survival time),and the median survival time of branched patients was 33.8 months (95%CI:16.8 to 38.5);The median survival time of lobe patients was 25.0 months (95%CI:13.6 to 58.7). The result of Log-rank test between groups indicated that the median survival time of patients with segmental type was better than that of patients with branch and lobe type(HR=2.03,95%CI:1.24 to 3.64,P=0.006);There was no significant difference in survival time between patients with branch type and lobe type (P=0.685). The results of the multivariate analysis of the Cox risk ratio model suggested that the actual anatomical location classification (HR=2.32,95%CI:1.10 to 4.92,P=0.028) and the postoperative lymph node metastasis rate (HR=2.06,95%CI:1.24 to 3.45,P=0.005) were independent factors related to survival after radical resection of IHCC patients. Conclusion: It is simple and convenient to classify resectable IHCC by actual anatomy,which can be used to preliminarily judge the prognosis of patients and provide a feasible classification scheme for the clinic.
Collapse
Affiliation(s)
- Y Jin
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| | - D Ye
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| | - H Geng
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| | - Y Q Yu
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| | - X X Zhang
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| | - S Y Peng
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| | - J T Li
- Department of Hepatopancreatobiliary Surgery,Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China
| |
Collapse
|
15
|
Chung B, Huang J, Uemura H, Choi Y, Ye Z, Suzuki H, Kang T, He D, Joung J, Brookman-May S, McCarthy S, Bhaumik A, He J, Mundle S, Chowdhury S, Agarwal N, Ye D, Chi K, Uemura H. 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
16
|
Ye D, Liu R, Luo H, Han W, Lu X, Cao L, Guo P, Liu J, Yue Y, Lu C. 597P A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
17
|
Yang Y, Wu J, Wang X, Yao J, Lao KS, Xu Y, Hu Y, Pan Y, Feng Y, Shi S, Zhang J, Qiao Y, Li Q, Ye D, Wang Y. P–389 The relationship between serum hormone profiles and missed abortion in humans. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Study question
Are circulating profiles of metabolic-related hormones also associated with the missed abortion (MA) in humans?
Summary answer
Serum levels of fatty acid-binding protein–4 (FABP4) and fibroblast growth factor 21 (FGF21) are positively associated with MA.
What is known already
A cluster of endocrine hormones, including FABP4, FGF21, adiponectin, lipocalin–2 (LCN2), exhibit pleiotropic effects on regulating systematic metabolism. Serum levels of them are associated with gestational obesity and diabetes and affect pregnancy outcomes, however, the relationship between their circulating profiles and MA is under-investigated.
Study design, size, duration
78 patients with MA and 86 healthy pregnant subjects matching on maternal age and body mass index (BMI) were nested from a prospective cohort in the Chinese population.
Participants/materials, setting, methods
Fasting serum samples from all participants were collected to test their serum levels of FGF21, FABP4, adiponectin, and LCN2 by enzyme-linked immunosorbent assay method (ELISA).
Main results and the role of chance
There were no significant differences in circulating profiles of adiponectin and LCN2 between MA patients and healthy pregnant subjects. By contrast, circulating levels of FGF21 and FABP4 were significantly and independently elevated in patients with MA relative to control cases even after adjusting confounding factors (for FGF21: MA: 28.96 ± 2.17 ng/ml; HP: 19.18 ± 1.12 ng/ml, P < 0.001, for FABP4: MA: 152.50 ± 9.31 pg/ml; HP: 90.86 ± 4.14 pg/ml, P < 0.001). Linear regression analysis showed, FGF21 raised every 10 pg/ml contributed to a 24% (95% CI: 15% - 34%) increase in the risk of MA, whereas the OR of FABP4 for the risk of MA was 1.052 (95% CI: 1.022 –1.088). Furthermore, using serum FGF21 level or FABP4 levels discriminated MA from healthy controls with an area under the operating characteristic’s curve (AUROC) of 0.81 (95% CI 0.76–0.92) and 0.70 (95% CI 0.62 - 0.78), respectively.
Limitations, reasons for caution
The study is limited by the sample size. In addition, our results were based-on Chinese population, whether it could be observed in other ethics group remain to be investigated. Meanwhile, the cause-effect relationship between increased serum FGF21 level and MA remains to be explored.
Wider implications of the findings: Our data would suggest that serum levels of FGF21 and FABP4 are associated with MA. Moreover, circulating FGF21 levels may serve as a potential diagnostic biomarker for the recognition of M.
Trial registration number
IRB Ref. No.: KY201913
Collapse
Affiliation(s)
- Y Yang
- Shaanxi University of Chinese Medicine, The Second Clinical Medical College, Xianyang, China
| | - J Wu
- The University of Hong Kong, State Key Laboratory of Pharmaceutical Biotechnology, Hong Kong SAR, China
| | - X Wang
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - J Yao
- Guangdong Pharmaceutical University, Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangzhou, China
| | - K S Lao
- The University of Hong Kong, Centre for Safe Medication Practice and Research, Hong Kong SAR, China
| | - Y Xu
- Guangdong Pharmaceutical University, The First Affiliated Hospital/School of Clinical Medicine, Guangzhou, China
| | - Y Hu
- The University of Hong Kong, State Key Laboratory of Pharmaceutical Biotechnology, Hong Kong SAR, China
| | - Y Pan
- Shenzhen University, School of Biomedicine Science, Shenzhen, China
| | - Y Feng
- Shaanxi University of Chinese Medicine, The Second Clinical Medical College, Xianyang, China
| | - S Shi
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - J Zhang
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - Y Qiao
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - Q Li
- Shaanxi University of Chinese Medicine, The Second Clinical Medical College, Xianyang, China
| | - D Ye
- Guangdong Pharmaceutical University, Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangzhou, China
| | - Y Wang
- The University of Hong Kong, State Key Laboratory of Pharmaceutical Biotechnology, Hong Kong SAR, China
| |
Collapse
|
18
|
Ye D, Veen L, Nikishova A, Lakhlili J, Edeling W, Luk OO, Krzhizhanovskaya VV, Hoekstra AG. Uncertainty quantification patterns for multiscale models. Philos Trans A Math Phys Eng Sci 2021; 379:20200072. [PMID: 33775139 PMCID: PMC8059643 DOI: 10.1098/rsta.2020.0072] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 10/26/2020] [Indexed: 05/06/2023]
Abstract
Uncertainty quantification (UQ) is a key component when using computational models that involve uncertainties, e.g. in decision-making scenarios. In this work, we present uncertainty quantification patterns (UQPs) that are designed to support the analysis of uncertainty in coupled multi-scale and multi-domain applications. UQPs provide the basic building blocks to create tailored UQ for multiscale models. The UQPs are implemented as generic templates, which can then be customized and aggregated to create a dedicated UQ procedure for multiscale applications. We present the implementation of the UQPs with multiscale coupling toolkit Multiscale Coupling Library and Environment 3. Potential speed-up for UQPs has been derived as well. As a proof of concept, two examples of multiscale applications using UQPs are presented. This article is part of the theme issue 'Reliability and reproducibility in computational science: implementing verification, validation and uncertainty quantification in silico'.
Collapse
Affiliation(s)
- D. Ye
- Computational Science Lab, Informatics Institute, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands
| | - L. Veen
- Netherlands eScience Center, Amsterdam, The Netherlands
| | - A. Nikishova
- Computational Science Lab, Informatics Institute, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands
| | - J. Lakhlili
- Max Planck Institute for Plasma Physics, Garching, Germany
| | - W. Edeling
- Scientific Computing Group, Centrum Wiskunde and Informatica, Amsterdam, The Netherlands
| | - O. O. Luk
- Max Planck Institute for Plasma Physics, Garching, Germany
| | - V. V. Krzhizhanovskaya
- Computational Science Lab, Informatics Institute, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands
- ITMO University, Saint Petersburg, Russia
| | - A. G. Hoekstra
- Computational Science Lab, Informatics Institute, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
19
|
Dai B, Zhang J, Wang H, Wang Q, Kong Y, Zhu Y, Qin X, Lin G, Ye D. 618MO Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.877] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Wei Y, Wu J, Zhu Y, Ye D. Prognostic value of germline DNA repair gene mutations in de novo metastatic and treatment-naïve prostate cancer. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33719-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
21
|
Chengyuan G, Wu J, Jin S, Ye D. Germline DNA damage repair gene mutation landscape and clinical relevance in early-onset upper tract urothelial carcinoma patients. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34081-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
22
|
Wei Y, Wu J, Zhu Y, Ye D. Prevalence of mutations in a comprehensive DNA damage repair gene panel in Chinese prostate cancer patients. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33642-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
23
|
Qu Y, Xu W, Tian X, Zhu Y, Zhang H, Ye D, An Wai Er A. Screening, identification and validation of CCND1 and PECAM1/CD31 in predicting prognosis for renal cell carcinoma patients. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33911-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
24
|
Bandini M, Zhu Y, Ye D, Ornellas A, Watkin N, Ager M, Hakenberg O, Heidenreich A, Raggi D, Catanzaro M, Haidl F, Mazzone E, Pederzoli F, Marandino L, Briganti A, Montorsi F, Chipollini J, Azizi M, Albersen M, Brower O, Spiess P, Necchi A. Regression-tree analysis for identifying the best candidates to neoadjuvant chemotherapy in patients with clinical node-positive penile squamous-cell carcinoma. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)34119-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
25
|
Yang WJ, Zhang YJ, Yan X, Ye D, Wang J, Liao Y, Yang YY, Zhang W, Wang Z, Wang ZQ, Xu SQ, Wang XL. [Recommendations for public health protection against flood disaster]. Zhonghua Yu Fang Yi Xue Za Zhi 2020; 54:124-128. [PMID: 32074696 DOI: 10.3760/cma.j.issn.0253-9624.2020.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Flood disaster is one of the most serious natural disasters in the world, and it could pose an inestimable impact on the affected people. Based on existing laws, regulations, and emergency manuals in China, extensive literature review, epidemiological and related protection evidence, and expert consultation, this study analyzed different health risk factors of flood disaster and proposed a multi-stage, multi-population, and multi-phase comprehensive protection measures for the public in the perspective of pre-event prevention, in-event intervention and post-event rescue strategy, which could provide a scientific basis for improving the level of public health protection against the flood disaster and corresponding health outcomes.
Collapse
Affiliation(s)
- W J Yang
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - Y J Zhang
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - X Yan
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - D Ye
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - J Wang
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - Y Liao
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - Y Y Yang
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - W Zhang
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| | - Z Wang
- Center for Health Emergency Response, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Z Q Wang
- Department of Environmental Health, Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China
| | - S Q Xu
- Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430074, China
| | - X L Wang
- National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing 100021, China
| |
Collapse
|
26
|
Deng Y, Li S, Ye D, Jiang H, Tang B, Zhou G. Synthesis and a Photo-Stability Study of Organic Dyes for Electro-Fluidic Display. Micromachines (Basel) 2020; 11:mi11010081. [PMID: 31940831 PMCID: PMC7019634 DOI: 10.3390/mi11010081] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Revised: 12/31/2019] [Accepted: 01/07/2020] [Indexed: 11/16/2022]
Abstract
Electro-fluidic display (EFD) is one of the most promising reflective displays because of its full color and video speed. Colored EFD oil, which normally consists of soluble organic dyes and non-polar solvent, plays a critical role in color, electro-optical behavior, and the reliability of the EFD devices. In this paper, we report our research on two kinds of electro-fluidic dyes based on anthraquinone and azo pyrazolone, including their synthesis, structure characterization, and application properties. Changes of absorbance curves, color coordinates of oils, and photoelectric responses of devices were studied in detail under accelerated irradiation to investigate the photo-stability and reliability properties of synthesized oil materials and devices. Photoelectric responses and photo stability of dyes are highly varied depending on their structures. We found that 1,4-dlialkylamino anthraqinone and mono azo pyrazolone dyes are much more stable than 1,8-dlialkylamino anthraqinone and corresponding bisazo pyrazolone dyes.
Collapse
Affiliation(s)
- Yong Deng
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou 510006, China; (Y.D.); (S.L.); (H.J.); (G.Z.)
- Shenzhen Guohua Optoelectronics Tech. Co. Ltd., Shenzhen 518110, China;
- Academy of Shenzhen Guohua Optoelectronics, Shenzhen 518110, China
| | - Shi Li
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou 510006, China; (Y.D.); (S.L.); (H.J.); (G.Z.)
| | - Dechao Ye
- Shenzhen Guohua Optoelectronics Tech. Co. Ltd., Shenzhen 518110, China;
- Academy of Shenzhen Guohua Optoelectronics, Shenzhen 518110, China
| | - Hongwei Jiang
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou 510006, China; (Y.D.); (S.L.); (H.J.); (G.Z.)
| | - Biao Tang
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou 510006, China; (Y.D.); (S.L.); (H.J.); (G.Z.)
- Correspondence: ; Tel.: +020-39314813
| | - Guofu Zhou
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays, South China Academy of Advanced Optoelectronics, South China Normal University, Guangzhou 510006, China; (Y.D.); (S.L.); (H.J.); (G.Z.)
- Shenzhen Guohua Optoelectronics Tech. Co. Ltd., Shenzhen 518110, China;
- Academy of Shenzhen Guohua Optoelectronics, Shenzhen 518110, China
| |
Collapse
|
27
|
Abstract
Electro-fluidic displays (EFDs) are one of the most promising reflective displays due to their full color and video speed.
Collapse
Affiliation(s)
- Shi Li
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays
- South China Academy of Advanced Optoelectronics
- South China Normal University
- Guangzhou 510006
- P. R. China
| | - Dechao Ye
- Shenzhen Guohua Optoelectronics Tech. Co. Ltd
- Shenzhen 518110
- P. R. China
- Academy of Shenzhen Guohua Optoelectronics
- Shenzhen 518110
| | - Alex Henzen
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays
- South China Academy of Advanced Optoelectronics
- South China Normal University
- Guangzhou 510006
- P. R. China
| | - Yong Deng
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays
- South China Academy of Advanced Optoelectronics
- South China Normal University
- Guangzhou 510006
- P. R. China
| | - Guofu Zhou
- Guangdong Provincial Key Laboratory of Optical Information Materials and Technology & Institute of Electronic Paper Displays
- South China Academy of Advanced Optoelectronics
- South China Normal University
- Guangzhou 510006
- P. R. China
| |
Collapse
|
28
|
Chung B, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Özgüroğlu M, Juárez Soto Á, Merseburger A, Uemura H, Ye D, Given R, Miladinovic B, Li N, Hudgens S, Floden L, Lopez-Gitlitz A, Chi K, Agarwal N. Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, Hu H, Huang J, Zhu S, Jin J, Ma L, Guo J, Xiao J, Park S, Zhang D, Qiu X, Bao Y, Zhang L, Shen W, Feng B. First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in Asian patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Gomes AJPDS, Chung B, Özgüroğlu M, Soto ÁJ, Merseburger A, Uemura H, Ye D, Given R, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi K. Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
31
|
Liu Y, Meng F, Ye D, Qi N. Camera-aided autocollimation approach for increasing the effective measurement range of a photoelectric collimator. Rev Sci Instrum 2019; 90:096106. [PMID: 31575221 DOI: 10.1063/1.5099997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Accepted: 08/12/2019] [Indexed: 06/10/2023]
Abstract
A camera aided autocollimation (CAAC) system is proposed to enhance the working range of a photoelectric collimator (PEC). This system consists of a camera surrounded by point light sources (LSs), a PEC, a rotary table, and a translation stage. As the tilt angle of the target varies, the intensity of the light from the LSs that is reflected by the target and received by the camera exhibits two symmetric peaks. The camera guides the target into the scope of the PEC by scanning these two peaks. This CAAC approach can automatically collimate a prism with an edge length of 10 mm and an initial tilt angle of 5° at a working range of 1.5 m. The error of the coarse collimation at 99.7% confidence is 602″.
Collapse
Affiliation(s)
- Y Liu
- Harbin Institute of Technology, Harbin 150001, China
| | - F Meng
- Dalian Shinergy Science and Technology Development Company Limited, Dalian 116600, China
| | - D Ye
- Harbin Institute of Technology, Harbin 150001, China
| | - N Qi
- Harbin Institute of Technology, Harbin 150001, China
| |
Collapse
|
32
|
Gu M, Cheng Q, Wang X, Yuan F, Sam NB, Pan H, Li B, Ye D. The impact of SLE on health-related quality of life assessed with SF-36: a systemic review and meta-analysis. Lupus 2019; 28:371-382. [PMID: 30813871 DOI: 10.1177/0961203319828519] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To evaluate the impact of systemic lupus erythematosus (SLE) on health-related quality of life (HRQoL) assessed with SF-36 and explore factors associated with HRQoL in SLE patients. METHODS A random-effect meta-analysis was performed to calculate extracted data. Sensitivity and subgroup analyses were performed to distinguish sources of heterogeneity. RESULTS A total of 36 articles were finally included in this meta-analysis, including 6510 patients. The pooled mean scores of SF-36 physical component summary and mental component summary were 46.10 (95% confidence interval (CI): 43.09-49.10) and 50.37 (95% CI: 47.78-52.87), respectively. Spearman's correlation analysis found that mean age, proportion of female participants, and publication decades were negatively associated with some of the SF-36 domains. Sample size and SLEDAI were positively associated with some of the SF-36 domains. Patients with SLE have lower HRQoL in comparison to the general population. CONCLUSIONS SLE has a significant impact on HRQoL, which proves that the necessity of improving HRQoL in SLE patients cannot be ignored. Measuring HRQoL should be considered as an indispensable part of the overall evaluation of health conditions of SLE patients.
Collapse
Affiliation(s)
- M Gu
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - Q Cheng
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - X Wang
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - F Yuan
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - N B Sam
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - H Pan
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - B Li
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| | - D Ye
- 1 Department of Epidemiology and Biostatistics, Anhui Medical University, Hefei, China.,2 Anhui Province Key Laboratory of Major Autoimmune Disease, Hefei, China
| |
Collapse
|
33
|
Hanker AB, Koch JP, Ye D, Sliwoski G, Sheehan J, Kinch LN, Red Brewer M, He J, Miller VA, Lalani AS, Cutler RE, Croessmann S, Zabransky DJ, Meiler J, Arteaga CL. Abstract PD3-05: Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd3-05] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against breast cancers harboring HER2 activating mutations, suggesting these tumors depend on HER2 signaling. Co-occurring HER2 and HER3 (ERBB3) mutations have been reported in patients who respond to neratinib (Hanker et al., Cancer Discov. 2017) suggesting the possibility of cooperativity of both oncogenes. Co-expression of the mutant intracellular domains of HER2 and HER3 in HEK293 cells enhanced phosphorylation of HER3 and ERK compared to expression of either mutant alone, which was blocked by 100 nM neratinib. Interrogation of TCGA, METABRIC, Project GENIE, and Foundation Medicine datasets revealed that gain-of-function mutations in ERBB2 and ERBB3 co-occur with a statistically significant frequency. For example, in GENIE, ERBB2 mutations co-occur with mutations in ERBB3 (8.3% of ERBB2-mutant vs 2.3% of ERBB2 WT; q=1.37x10-10).
We hypothesized that co-occurring mutations in HER2 and HER3 cooperate to enhance HER2 signaling and dependence and breast cancer progression.
Thirty-four unique breast cancers were found to harbor co-occurring mutations in HER2 and HER3, the most common of which were ERBB2L755S/ERBB3E928G (n=10), ERBB2V777L/ERBB3E928G(n=6), and ERBB2L869R/Q/ERBB3E928G (n=4). Using co-immunoprecipitation assays with HER2 and HER3 antibodies in transfected HEK293 cells, we found that co-expression of HER3E928G with wild type (WT) HER2, or co-expression of HER2L755S or HER2L869R with HER3WT, slightly increased HER2-HER3 dimerization. However, binding was strongest between double mutants. This was accompanied by the highest levels of Y1289 p-HER3 in cells expressing both HER3E928G and each HER2L755S, HER2V777L, or HER2L869R compared to cells expressing each HER2 or HER3 mutant with a respective WT heterodimer partner. Structural modeling of the HER2L869R/HER3E928G double-mutant predicted that the HER3 mutation, located at the dimer interface, may enhance heterodimerization of the kinase domains through decreased bulk and electrostatic repulsion. We also noted that the HER2L755S mutation is predicted to be in close proximity to HER3E928G (<4 Å) and may impact binding affinity. Investigation of the structural basis for the enhanced binding of other double mutants is in progress.
MCF7 “knock-in” cells incorporating HER2L755S, HER2V777L, or HER2L869R (or HER2WT) were stably transduced with HER3E928G or HER3WT. Co-expression of double mutants strongly enhanced estrogen-independent growth in 3D Matrigel over cells expressing either mutant alone. We are currently testing inhibitors of HER2/HER3 signaling, including neratinib ± trastuzumab, trastuzumab + pertuzumab, and the ERBB1-3 antibody mixture Sym013, to determine therapeutic strategies to block the cooperative growth induced by co-occurring HER2 and HER2 mutations.
Conclusions: Co-expression of mutant HER2 and mutant HER3 promotes HER2/HER binding, HER3 phosphorylation, and breast tumor cell proliferation. We aim to identify therapeutic vulnerabilities for patients with co-occurring HER2 and HER3 mutations.
Citation Format: Hanker AB, Koch JP, Ye D, Sliwoski G, Sheehan J, Kinch LN, Red Brewer M, He J, Miller VA, Lalani AS, Cutler, Jr. RE, Croessmann S, Zabransky DJ, Meiler J, Arteaga CL. Co-occurring gain-of-function mutations in HER2 and HER3 cooperate to enhance HER2/HER3 binding, HER-dependent signaling, and breast cancer growth [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD3-05.
Collapse
Affiliation(s)
- AB Hanker
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - JP Koch
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - D Ye
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - G Sliwoski
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - J Sheehan
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - LN Kinch
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - M Red Brewer
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - J He
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - VA Miller
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - AS Lalani
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - RE Cutler
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - S Croessmann
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - DJ Zabransky
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - J Meiler
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| | - CL Arteaga
- UT Southwestern Medical Center, Nashville, TN; Vanderbilt University Medical Center, Nashville, TN; Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Puma Biotechnology, Los Angeles, CA; Johns Hopkins University, Baltimore, MD
| |
Collapse
|
34
|
Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018; 29:2371-2378. [PMID: 30346481 PMCID: PMC6311952 DOI: 10.1093/annonc/mdy454] [Citation(s) in RCA: 158] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Background The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. Patients and methods In a phase III, randomized, double-blind trial, patients had >50% clear-cell RCC, had undergone nephrectomy, and had no evidence of macroscopic residual or metastatic disease [independent review committee (IRC) confirmed]. The intent-to-treat population included all randomized patients [≥pT2 and/or N+, any Fuhrman grade (FG), Eastern Cooperative Oncology Group status 0/1]. Patients (stratified by risk group/country) received (1 : 1) oral twice-daily axitinib 5 mg or placebo for ≤3 years, with a 1-year minimum unless recurrence, occurrence of second primary malignancy, significant toxicity, or consent withdrawal. The primary end point was disease-free survival (DFS) per IRC. A prespecified DFS analysis in the highest-risk subpopulation (pT3, FG ≥ 3 or pT4 and/or N+, any T, any FG) was conducted. Results A total of 724 patients (363 versus 361, axitinib versus placebo) were randomized from 8 May 2012, to 1 July 2016. The trial was stopped due to futility at a preplanned interim analysis at 203 DFS events. There was no significant difference in DFS per IRC [hazard ratio (HR) = 0.870; 95% confidence interval (CI) : 0.660-1.147; P = 0.3211). In the highest-risk subpopulation, a 36% and 27% reduction in risk of a DFS event (HR; 95% CI) was observed per investigator (0.641; 0.468-0.879; P = 0.0051), and by IRC (0.735; 0.525-1.028; P = 0.0704), respectively. Overall survival data were not mature. Similar adverse events (AEs; 99% versus 92%) and serious AEs (19% versus 14%), but more grade 3/4 AEs (61% versus 30%) were reported for axitinib versus placebo. Conclusions ATLAS did not meet its primary end point; however, improvement in DFS per investigator was seen in the highest-risk subpopulation. No new safety signals were reported. Trial registration number NCT01599754.
Collapse
Affiliation(s)
- M Gross-Goupil
- Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - T G Kwon
- Department of Urology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
| | - M Eto
- Department of Urology, Kyushu University, Fukuoka, Japan
| | - D Ye
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - H Miyake
- Department of Urology, Hamamatsu University, Hamamatsu, Japan
| | - S I Seo
- Department of Urology, Sungkyunkwan University, Seoul, Republic of Korea
| | - S-S Byun
- Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - J L Lee
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - V Master
- Department of Urology, Emory University School of Medicine, Atlanta, USA
| | - J Jin
- Department of Urology, Peking University First Hospital and Institute of Urology, Beijing, China
| | | | - R Linke
- SFJ Pharmaceuticals, Inc, Pleasanton, USA
| | - M Casey
- Pfizer Inc, Collegeville, USA
| | | | - M Lechuga
- Pfizer Srl, Global Product Development, Milan, Italy
| | - O Valota
- Pfizer Srl, Global Product Development, Milan, Italy
| | - E Grande
- Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| | - D I Quinn
- Department of Medical Oncology, USC Keck School of Medicine Norris Comprehensive Cancer Center, Los Angeles, USA.
| |
Collapse
|
35
|
Kanesvaran R, Uemura H, Ye D, Chiong E, Lojanapiwat B, Pu YS, Kumar Rawal S, Razack A, Zeng H, Chung B, Tsai YS, Noor Ashani M, Liu Y, Asinas-Tan M, Liu W, Low G, van Kooten Losio M. United in Fight against prOstate cancer registry (UFO): Treatment patterns and quality of life from a large, multi-center, longitudinal cohort study in Asia. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Abstract
Human dental pulp stem cells (hDPSCs) reside in postnatal dental pulp and exhibit the potential to differentiate into odontoblasts as well as neurons. However, the intercellular signaling niches necessary for hDPSC survival and self-renewal remain largely unknown. The objective of this study is to demonstrate the existence of intercellular purinergic signaling in hDPSCs and to assess the impact of purinergic signaling on hDPSC survival and proliferation. hDPSCs were isolated from extracted third molars and cultured in minimum essential medium. To demonstrate responsiveness to ATP application and inhibitions by purinergic receptor antagonists, whole cell patch-clamp recordings of ATP-induced currents were recorded from cultured hDPSCs. Immunofluorescence and enzymatic histochemistry staining were performed to assess purinergic receptor expression and ectonucleotidase activity in hDPSCs, respectively. To determine the effects of purinergic signaling on hDPSC, purinergic receptor antagonists and an ectonucleotidase inhibitor were applied in culture medium, and hDPSC survival and proliferation were assessed with DAPI staining and Ki67 immunofluorescence staining, respectively. We demonstrated that ATP application induced inward currents in hDPSCs. P2X and P2Y receptors are involved in the generation of ATP-induced inward currents. We also detected expression of NTPDase3 and ectonucleotidase activity in hDPSCs. We further demonstrated that purinergic receptors were tonically activated in hDPSCs and that inhibition of ectonucleotidase activity enhanced ATP-induced inward currents. Furthermore, we found that blocking P2Y and P2X receptors reduced-and inhibition of ecto-ATPase activity enhanced-the survival and proliferation of hDPSCs, while blocking P2X receptors alone affected only hDPSC proliferation. Autocrine/paracrine purinergic signaling is essential for hDPSC survival and proliferation. These results reveal potential targets to manipulate hDPSCs to promote tooth/dental pulp repair and regeneration.
Collapse
Affiliation(s)
- S Zhang
- 1 Department of Dentistry, Eastman Institute for Oral Health, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - D Ye
- 1 Department of Dentistry, Eastman Institute for Oral Health, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - L Ma
- 2 Department of Dentistry, School of Stomatology, Zhengzhou University, Zhengzhou, China, China
| | - Y Ren
- 1 Department of Dentistry, Eastman Institute for Oral Health, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - R T Dirksen
- 3 Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - X Liu
- 1 Department of Dentistry, Eastman Institute for Oral Health, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.,3 Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.,4 Department of Dentistry, Atlanta VA Medical Center, Decatur, GA, USA
| |
Collapse
|
37
|
Uemura H, Ye D, Kanesvaran R, Zeng H, Pu YS, Chiong E, Lojanapiwat B, Rawal S, Chung B, Razack A, Tsai YS, Liu Y, Asinas-Tan M, Liu W, Low G, van Kooten Losio M. United in fight against prostate cancer registry (UFO): First results from a large, multi-center, prospective, longitudinal cohort study in Asia. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Qin X, Ye D. Implementation of National Health Reform on China Genitourinary Multidisciplinary Team Consultation Platform. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.41800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background and context:: Comprehensive management of multidisciplinary team (MDT) is the most effective mode in genitourinary(GU) cancers. Due to the uneven level in the management of GU cancers in China, top GU MDT services do not meet the medical needs of people. The blooming of “Internet+” mode promotes remote medical services, and is supported by health administrations. Aim: The country wide accessibility of high level medical services, and national health reform, especially in the field of GU cancers, will be addressed by the project. Strategy/Tactics: We developed an Internet platform of MDT management for GU cancers across China: “China GU MDT Consultation Platform (CUMP)”. Led by senior clinical staffs, and based on advanced internet and mobile technologies, CUMP is to meet the needs of clinical practices. With compatibility, universality and practicality, CUMP has the following advantages: unified data management, flexible models, stable and reliable remote video conference system, efficient cooperation, and convenient participation. Program/Policy process: Recruit top GU MDT and experts in China, and make consensus and guidelines of the implementations of MDT in GU cancers; Help other local institutions develop GU MDT and provide services, which are authenticated by the platform; Build a system that a single patient can receive top level GU MDT service locally and remotely, provided by the platform. Outcomes: Since April 2017, CUMP has successfully carried out remote MDT consultations involved 16 medical centers with GU MDT services or individual GU experts across China. As a start, 18 difficult cases were discussed and managed. More than 600 Chinese GU experts from medical institutions at all levels, have registered on CUMP, ready for submitting or accepting MDT service; another 34 top Chinese GU MDT units are on the waiting list to be technically authorized on CUMP. One Chinese consensus on the implementation of GU MDT was released last December. What was learned: The project was relevant to current obstacles in China's health reform by greatly enhancing the accessibility of GU MDT service. The majority of GU cancer patients can receive domestic top-level MDT service in a local institution; this project also helped to provide a great convenience to the development of local MDT service, so as to improve medical qualities, especially in GU cancers in different regions of China. The project made the technology and medical service transcend the boundary of administrative division and institution.
Collapse
Affiliation(s)
- X. Qin
- Fudan University Shanghai Cancer Center, Urology, Shanghai, China
| | - D. Ye
- Fudan University Shanghai Cancer Center, Urology, Shanghai, China
| | | |
Collapse
|
39
|
Zhu M, Li M, Zhou Y, Dangelmajer S, Kahlert UD, Xie R, Xi Q, Shahveranov A, Ye D, Lei T. Isoflurane enhances the malignant potential of glioblastoma stem cells by promoting their viability, mobility in vitro and migratory capacity in vivo. Br J Anaesth 2018; 116:870-7. [PMID: 27199319 DOI: 10.1093/bja/aew124] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/15/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Isoflurane is one of the most common general anaesthetics used during surgical procedures, including tumour resection. However, the effects of isoflurane on the viability and migration capacity of cancer cells, specifically in the context of brain cancer cells, remain unclear. Therefore, the aim of this study was to evaluate the influence that isoflurane has on the function of glioblastoma stem cells (GCSs) in regards to cell proliferation, survival and migration. METHOD U251-GSCs were exposed to isoflurane at clinically relevant concentrations and incubation times. The effects on proliferation, survival and migration capacities of the cells were evaluated in vitro. The potential risk was assessed in mice by intracranial injection of U251-GSCs pretreated with isoflurane. Furthermore, the average tumour volume and migration distance of U251-GSCs from the tumour centre were calculated. RESULTS Exposure of U251-GSCs to 1.2% isoflurane for 6 h resulted in increased proliferation (P<0.05) and decreased apoptosis rate (P<0.05) when compared with the control group. In addition, isoflurane exposure caused increased migration capacity in vitro (P<0.05) and the distance migrated was increased in vivo (P<0.05). CONCLUSION Clinically relevant concentrations and incubation times of isoflurane could promote the viability and mobility of U251-GSCs, suggesting this general anaesthetic may have detrimental effects in glioblastoma by facilitating its growth and migration.
Collapse
Affiliation(s)
- M Zhu
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - M Li
- Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - Y Zhou
- Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - S Dangelmajer
- Stanford University School of Medicine, Palo Alto, CA, USA
| | - U D Kahlert
- Department of Pathology, Division of Neuropathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA Department of Neurosurgery, University Medical Center Düsseldorf, Düsseldorf, Germany
| | - R Xie
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - Q Xi
- Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - A Shahveranov
- Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - D Ye
- Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| | - T Lei
- Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, People's Republic of China
| |
Collapse
|
40
|
Gao J, Zhu C, Zhang Y, Sheng Y, Luo X, Ye D, Sun L. 841 Association study and fine mapping major histocompatibility complex analysis in pemphigus vulgaris of Han Chinese population. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Ye D, Karnati SKR, Wagner B, Firkins JL, Eastridge ML, Aldrich JM. Essential oil and monensin affect ruminal fermentation and the protozoal population in continuous culture. J Dairy Sci 2018; 101:5069-5081. [PMID: 29605331 DOI: 10.3168/jds.2017-13646] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Accepted: 02/01/2018] [Indexed: 12/29/2022]
Abstract
The interaction of monensin and essential oil was hypothesized to suppress protozoa and methane production while maintaining normal rumen function. The objective of this study was to determine the effects of feeding monensin (MON) and CinnaGar (CIN, a commercial blend of cinnamaldehyde and garlic oil; Provimi North America, Brookville, OH) on ruminal fermentation characteristics. Continuous culture fermentors (n = 4) were maintained in 4 experimental periods in a 4 × 4 Latin square design. Four dietary treatments were arranged in a 2 × 2 factorial: (1) control diet, 37 g/d of dry matter (40 g/d at ∼92.5% dry matter) of a 50:50 forage:concentrate diet containing no additive; (2) MON at 11 g/909 kg of dry matter; (3) CIN at 0.0043% of dry matter; and (4) a combination of MON and CIN at the levels in (2) and (3). Treatment had no effects on protozoal populations, concentration of NH3N, total N flow of effluent, production of total volatile fatty acids, or flows of conjugated linoleic acid and total C18 fatty acids. The MON decreased acetate:propionate ratio and biohydrogenation of both total C18 and 18:1 cis-9 but increased protozoal generation time, concentration of peptide, and flow of 18:1 trans-11. The MON tended to decrease protozoal counts in effluent and flow of 18:0 but tended to increase propionate production. The CIN decreased true organic matter digestibility and protozoal N flow of effluent but increased nonammonia, nonmicrobial N flow. The CIN tended to decrease protozoal counts, microbial N flow, and neutral detergent fiber digestibility but tended to increase biohydrogenation of total C18, 18:2, and 18:3. The CIN tended to increase isovalerate production. The MON and CIN tended to interact for increased methane production and bacterial N flow. A second experiment was conducted to determine the effects of MON and CIN on protozoal nitrogen and cell volume in vitro. Four treatments included (1) control (feed only), (2) feed + 0.0043% dry matter CIN, (3) feed + 2.82 μM MON, and (4) feed + CIN + MON at the same levels as in (2) and (3). With no interactions, MON addition decreased percentage of protozoa that were motile and tended to decrease cell volume at 6 h. The CIN did not affect cell count or other indicators of motility or volume at either 3 or 6 h. Under the conditions of our study, we did not detect an additive response for MON and CIN to decrease protozoal counts or methane production. A 3-dimensional method is suggested to better estimate protozoal cell volume.
Collapse
Affiliation(s)
- D Ye
- Department of Animal Sciences, The Ohio State University, Columbus 43210
| | - S K R Karnati
- Department of Animal Sciences, The Ohio State University, Columbus 43210
| | - B Wagner
- Department of Animal Sciences, The Ohio State University, Columbus 43210
| | - J L Firkins
- Department of Animal Sciences, The Ohio State University, Columbus 43210
| | - M L Eastridge
- Department of Animal Sciences, The Ohio State University, Columbus 43210.
| | | |
Collapse
|
42
|
Ye D, Bote S, Ouellet J, Ferland C. Preliminary analysis of a novel objective assessment of kinesiophobia in adolescent scoliosis patients scheduled for corrective surgery. The Journal of Pain 2018. [DOI: 10.1016/j.jpain.2017.12.113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Xiong Y, Xu W, Yang H, Wang P, Ma S, Zhao S, Ye D, Guan K. P08.65 The mechanisms of oncometabolites in epigenetic control, DNA repair, neural development and gliomagenesis. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Ye D, Ogura M. The 7th China–Japan Workshop on Environmental Catalysis and Eco-Materials was held in Guangzhou, China, November 6th–9th, 2015. Catal Today 2017. [DOI: 10.1016/j.cattod.2016.11.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Ye D, Fei Y, Sheng YE, Qiao JJ, Dong FQ. Analysis of a Chinese pedigree with trichorhinophalangeal syndrome derived from a missense mutation in the TRPS1
gene. Clin Exp Dermatol 2017; 42:432-434. [PMID: 28244134 DOI: 10.1111/ced.13082] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/25/2016] [Indexed: 11/30/2022]
Affiliation(s)
- D. Ye
- Department of Endocrinology and Metabolism; The First Affiliated Hospital; College of Medicine Zhejiang University; 79 Qing Chun Road Hang Zhou 310003 PR China
| | - Y. Fei
- Department of Endocrinology and Metabolism; People's Hospital of Fuyang City; Zhejiang Province PR China
| | - Y.-E. Sheng
- Department of Endocrinology and Metabolism; People's Hospital of Fuyang City; Zhejiang Province PR China
| | - J.-J. Qiao
- Department of Dermatology; The First Affiliated Hospital; College of Medicine Zhejiang University; 79 Qing Chun Road Hang Zhou 310003 PR China
| | - F.-Q. Dong
- Department of Endocrinology and Metabolism; The First Affiliated Hospital; College of Medicine Zhejiang University; 79 Qing Chun Road Hang Zhou 310003 PR China
| |
Collapse
|
46
|
Huang QC, Ye D, Jiang XY, Li QL, Yao KY, Wang JB, Jin MJ, Chen K. [Cost-effectiveness analysis on colorectal cancer screening program]. Zhonghua Liu Xing Bing Xue Za Zhi 2017; 38:65-68. [PMID: 28100379 DOI: 10.3760/cma.j.issn.0254-6450.2017.01.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the cost-effectiveness of colorectal cancer screening program in different age groups from the view of health economics. Methods: The screening compliance rates, detection rates in different age groups were calculated by using the data from colorectal cancer screening program in Jiashan county, Zhejiang province. The differences in indicator among age groups were analyzed with χ(2) test or trend χ(2) test. The ratios of cost to the number of case were calculated according to cost statistics. Results: The detection rates of immunochemical fecal occult blood test (iFOBT) positivity, advanced adenoma and colorectal cancer and early stage cancer increased with age, while the early diagnosis rates were negatively associated with age. After exclusion the younger counterpart, the cost-effectiveness of individuals aged >50 years could be reduced by 15%-30%. Conclusion: From health economic perspective, it is beneficial to start colorectal cancer screening at age of 50 years to improve the efficiency of the screening.
Collapse
Affiliation(s)
- Q C Huang
- Department of Epidemiology, School of Public Health, Zhejiang University, Hangzhou 310058, China
| | - D Ye
- Department of Epidemiology, School of Public Health, Zhejiang University, Hangzhou 310058, China
| | - X Y Jiang
- Department of Epidemiology, School of Public Health, Zhejiang University, Hangzhou 310058, China
| | - Q L Li
- General Office, Jiashan Institute for Cancer Prevention and Treatment, Jiashan 314100, China
| | - K Y Yao
- Registry Office, Jiashan Institute for Cancer Prevention and Treatment, Jiashan 314100, China
| | - J B Wang
- Department of Epidemiology, School of Public Health, Zhejiang University, Hangzhou 310058, China
| | - M J Jin
- Department of Epidemiology, School of Public Health, Zhejiang University, Hangzhou 310058, China
| | - K Chen
- Department of Epidemiology, School of Public Health, Zhejiang University, Hangzhou 310058, China
| |
Collapse
|
47
|
Ye D, Ahn H, Pu YS, Han W, Xie LP, Huang SP, Wu HC, Ma L, Qi J, Zhou F, Sun G, Chen L, Xue B, Yamada S, Saito M, Suga K, Sun Y. 286P Efficacy, safety and pharmacokinetics (PK) of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC): An Asian multinational study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw584.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Ye D, Smith E, O'Toole S, O'Leary J, Hennessy B, Xu X. A potential natural inhibitor in the autocrine regulation among ovarian stromal cell population & its translational implications. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw362.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
49
|
Ye D, Ahn H, Pu YS, Weiqing H, Xie LP, Huang SP, Wu HC, Ma L, Yamada S, Noda S, Sun Y. Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Chun Y, Kwon Y, Shin S, Ye D, Baek H. Activation of uPA-uPAR signaling pathway by human CYP1B1 promotes cancer progression and metastasis in human breast cancer cells. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|